Literature DB >> 11387214

Binding of Ikaros to the lambda5 promoter silences transcription through a mechanism that does not require heterochromatin formation.

P Sabbattini1, M Lundgren, A Georgiou, C Chow , G Warnes, N Dillon.   

Abstract

The Ikaros family of proteins are DNA binding factors required for correct development of B and T lymphocytes. Cytogenetic studies have shown that these proteins form complexes with pericentromeric heterochromatin in B cells, and the colocalization of transcriptionally silent genes with these complexes suggests that Ikaros could silence transcription by recruiting genes to heterochromatin. Here we show that a site in the lambda5 promoter that binds Ikaros and Aiolos is required for silencing of lambda5 expression in activated mature B cells. Analysis of methylation and nuclease accessibility indicates that the silenced lambda5 gene is not heterochromatinized in B cells, despite being associated with pericentromeric heterochromatin clusters. We also found that a promoter mutation, which affects Ikaros-mediated silencing of lambda5 expression, is not rescued in a transgenic line that has the gene integrated into pericentromeric heterochromatin. Our results indicate that the Ikaros proteins initiate silencing of lambda5 expression through a direct effect on the promoter with localization to pericentromeric heterochromatin likely to affect the action of Ikaros on regulatory sequences rather than causing heterochromatinization of the gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11387214      PMCID: PMC125479          DOI: 10.1093/emboj/20.11.2812

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  57 in total

Review 1.  Locus control regions and epigenetic chromatin modifiers.

Authors:  R Festenstein; D Kioussis
Journal:  Curr Opin Genet Dev       Date:  2000-04       Impact factor: 5.578

2.  Nuclear localization and histone acetylation: a pathway for chromatin opening and transcriptional activation of the human beta-globin locus.

Authors:  D Schübeler; C Francastel; D M Cimbora; A Reik; D I Martin; M Groudine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

3.  Transcription factor dosage affects changes in higher order chromatin structure associated with activation of a heterochromatic gene.

Authors:  M Lundgren; C M Chow; P Sabbattini; A Georgiou; S Minaee; N Dillon
Journal:  Cell       Date:  2000-11-22       Impact factor: 41.582

4.  Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding.

Authors:  B S Cobb; S Morales-Alcelay; G Kleiger; K E Brown; A G Fisher; S T Smale
Journal:  Genes Dev       Date:  2000-09-01       Impact factor: 11.361

5.  Activation of the beta globin locus by transcription factors and chromatin modifiers.

Authors:  T McMorrow; A van den Wijngaard; A Wollenschlaeger; M van de Corput; K Monkhorst; T Trimborn; P Fraser; M van Lohuizen; T Jenuwein; M Djabali; S Philipsen; F Grosveld; E Milot
Journal:  EMBO J       Date:  2000-09-15       Impact factor: 11.598

6.  Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin.

Authors:  K Hahm; B S Cobb; A S McCarty; K E Brown; C A Klug; R Lee; K Akashi; I L Weissman; A G Fisher; S T Smale
Journal:  Genes Dev       Date:  1998-03-15       Impact factor: 11.361

7.  5-Methylcytosine localised in mammalian constitutive heterochromatin.

Authors:  O J Miller; W Schnedl; J Allen; B F Erlanger
Journal:  Nature       Date:  1974-10-18       Impact factor: 49.962

8.  Heterochromatin protein 1 modifies mammalian PEV in a dose- and chromosomal-context-dependent manner.

Authors:  R Festenstein; S Sharghi-Namini; M Fox; K Roderick; M Tolaini; T Norton; A Saveliev; D Kioussis; P Singh
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

9.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06

10.  Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helix-loop-helix transcription factor E12.

Authors:  B L Kee; C Murre
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

View more
  37 in total

1.  Mast cell IL-4 expression is regulated by Ikaros and influences encephalitogenic Th1 responses in EAE.

Authors:  Gregory D Gregory; Shveta S Raju; Susan Winandy; Melissa A Brown
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

Review 2.  Gene positioning.

Authors:  Carmelo Ferrai; Inês Jesus de Castro; Liron Lavitas; Mita Chotalia; Ana Pombo
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-19       Impact factor: 10.005

Review 3.  Clinical consequences of defects in B-cell development.

Authors:  Andre M Vale; Harry W Schroeder
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

4.  Ikaros integrates endocrine and immune system development.

Authors:  Shereen Ezzat; Rene Mader; ShunJiang Yu; Terry Ning; Philippe Poussier; Sylvia L Asa
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  Ikaros represses the transcriptional response to Notch signaling in T-cell development.

Authors:  Eva Kleinmann; Anne-Solen Geimer Le Lay; MacLean Sellars; Philippe Kastner; Susan Chan
Journal:  Mol Cell Biol       Date:  2008-10-13       Impact factor: 4.272

6.  Ikaros in B cell development and function.

Authors:  Maclean Sellars; Philippe Kastner; Susan Chan
Journal:  World J Biol Chem       Date:  2011-06-26

7.  Ikaros is required for plasmacytoid dendritic cell differentiation.

Authors:  David Allman; Marc Dalod; Carine Asselin-Paturel; Thomas Delale; Scott H Robbins; Giorgio Trinchieri; Christine A Biron; Philippe Kastner; Susan Chan
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

8.  Regulator of myeloid differentiation and function: The secret life of Ikaros.

Authors:  Olivia L Francis; Jonathon L Payne; Rui-Jun Su; Kimberly J Payne
Journal:  World J Biol Chem       Date:  2011-06-26

9.  Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter.

Authors:  Shereen Ezzat; Shunjiang Yu; Sylvia L Asa
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia.

Authors:  Philippe Kastner; Arnaud Dupuis; Marie-Pierre Gaub; Raoul Herbrecht; Patrick Lutz; Susan Chan
Journal:  Am J Blood Res       Date:  2013-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.